Metformin beyond an anti-diabetic agent: A comprehensive and mechanistic review on its effects against natural and chemical toxins

Malaekeh-Nikouei, Amirhossein; Shokri-Naei, Sina; Karbasforoushan, Sobhan; Bahari, Hossein; Baradaran Rahimi, Vafa; Heidari, Reza; Askari, Vahid Reza

doi:10.1016/j.biopha.2023.115263

Cited by 11 publications

(2 citation statements)

References 311 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…treatment of diabetes, polycystic ovarian syndrome, cancer, metformin has been linked to a number of other health benefit ity to reduce the side effects of drugs like chemotherapy and in been supported by multiple lines of data [46,47]. Recent studies reported that MET can improve neurot caused by chemotherapeutic agents such as cyclophosphamid [46,48]. In addition, our recent study also evaluated the neuroto therapy on the function of the brain, and we also studied the fect that may be achieved by combining MET and CMF.…”

Section: Introductionmentioning

confidence: 99%

“…Consequently, the primary objective of this study is to e treatment on thyroid hormone levels and ascertain the potenti co-treatment in alleviating the deleterious consequences of CM Recent studies reported that MET can improve neurotoxicity and brain damage caused by chemotherapeutic agents such as cyclophosphamide and cisplatin in rodents [46,48]. In addition, our recent study also evaluated the neurotoxic effects induced by CMF therapy on the function of the brain, and we also studied the potentially ameliorative effect that may be achieved by combining MET and CMF.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The Impact of Metformin on the Development of Hypothyroidism and Cardiotoxicity Induced by Cyclophosphamide, Methotrexate, and Fluorouracil in Rats

Alhowail,

Aldubayan

2023

Pharmaceuticals

View full text Add to dashboard Cite

Cyclophosphamide (CYP), methotrexate (MTX), and 5-fluorouracil (5-FU) are extensively utilized in the therapeutic management of various malignancies. It is noteworthy, however, that potential chemotherapy-related complications include the occurrence of hypothyroidism and cardiotoxicity. Metformin (MET) is a pharmacological agent for managing type 2 diabetes. It has been reported to mitigate certain toxic manifestations associated with chemotherapy. This study’s primary objective is to investigate MET’s protective effects against hypothyroidism and cardiotoxicity induced by CMF treatment. A total of forty male rats were allocated into four distinct groups, each consisting of ten rats per group. These groups were categorized as follows: saline, MET, CMF, and CMF + MET. The experimental group of rats were administered CMF via intraperitoneal injection, receiving two doses of CMF, and fed MET in their daily drinking water, with a 2.5 mg/mL concentration. Blood samples were collected into EDTA tubes for assessment of TSH, free and total (T4 and T3), troponin I, CK, and CK-MB levels utilizing Electrochemiluminescence Immunoassays (ECI). The saline and MET groups did not exhibit significant alterations in thyroid hormones or cardiotoxic biomarkers. In contrast, in the CMF group, there was a notable reduction in T4, FT4, T3, and FT3 levels but no significant changes in TSH levels; however, troponin I, CK, and CK-MB levels were notably elevated. MET co-treatment with CMF did not ameliorate these effects caused by CMF. In conclusion, CMF treatment induced hypothyroidism and cardiotoxicity in rats, but MET co-treatment did not rescue the reduction of thyroid hormones or the elevation of cardiotoxic biomarkers.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%